Clinical Trials Webinar: Phase 2 Investigation of Intranasal Oxytocin with Dr. Eric Hollander
Dr. Hollander and his team from Montefiore Medical Center and Albert Einstein College of Medicine are conducting a Phase 2 study to investigate the effects of intranasal oxytocin (OXT) in children and adolescents with PWS. They will study how OXT administration impacts eating, repetitive behaviors, and social cognition in PWS. This webinar reviews the rationale for testing OXT in PWS, describes the study protocol and outcome measures, and reviews eligibility criteria. Click here to view the recorded webinar.
As of November 24th, this study is enrolling patients ages 5-8 with a confirmed diagnosis of Prader-Willi syndrome. Families who are interested in participating can contact Bonnie Taylor, Ph.D., Assistant Clinical Professor, at (718) 920-2909 or email email@example.com. Please note: multiple trips to the study site in New York City will be required for participation.
Funded by FPWR in partnership with PWSA(USA) as a “Best Idea Grants (BIG)” and with additional funds from Prader-Willi Angels, Dr. Eric Hollander from the Albert Einstein College of Medicine will focus on the effect of oxytocin on eating, repetitive behaviors, and social cognition in children with PWS, ages 5-18, with a confirmed Prader-Willi syndrome diagnosis and ASD features. (Note: children are NOT required to have an ASD diagnosis.)